MedTrace Logo

Efficacy of High-intensity Laser in Jaccoud's Arthropathy in Systemic Lupus Erythematosus

NCT04244539 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-01-28

No results posted yet for this study

Summary

A randomized, controlled study with the pretest-posttest design was performed; 50 patients who were suffered from jaccoud's arthropathy and aged 30-50 years. Patients were randomly assigned into two groups: Group 1 (study group): received HILT, in addition to the routine physical therapy program. Group 2 (control group): received routine physical therapy program. All treatment interventions were applied at a frequency of three sessions per week for 8 weeks. The participants were recruited from the air forces hospital at the period from December 2018 and October 2019.

Conditions

  • Musculoskeletal Diseases
  • Skin Diseases

Interventions

DEVICE

high-intensity laser Device.

Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • Nabil Mahmoud Abdel-Aal

    collaborator UNKNOWN

  • Jouf University

    lead OTHER

Principal Investigators

  • Nabil M Abdel-Aal, Assist.prof. · Cairo University, Faculty of physical Therapy.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2019-10-30
Completion
2019-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04244539 on ClinicalTrials.gov